PMID- 34283308
OWN - NLM
STAT- MEDLINE
DCOM- 20210825
LR  - 20210825
IS  - 1613-2246 (Electronic)
IS  - 0021-5155 (Linking)
VI  - 65
IP  - 5
DP  - 2021 Sep
TI  - Recovery of deepening of the upper eyelid sulcus after switching from 
      prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective 
      analysis.
PG  - 591-597
LID - 10.1007/s10384-021-00855-3 [doi]
AB  - PURPOSE: To examine the effect of switching from a prostanoid FP receptor 
      agonists to EP2 receptor agonist (omidenepag isopropyl) on the deepening of the 
      upper eyelid sulcus (DUES) and intraocular pressure (IOP) in Japanese glaucoma 
      patients over 3 months post treatment. STUDY DESIGN: Prospective observational 
      study. METHODS: Patients with glaucoma who received FP receptor agonists 
      treatment and had complained of DUES-related reduction in quality of life were 
      included. Their FP receptor agonists was switched to omidenepag isopropyl without 
      a drug holiday. At baseline and 1 and 3 months post-switch, photographs were 
      taken and the changes in DUES were assessed by three independent observers. IOP 
      and adverse events were also assessed. RESULTS: The study included 23 eyes of 23 
      patients (6 men, 17 women; average age, 60.6 years). After switching, DUES 
      improved in 12 eyes at 1 month and in 16 eyes at 3 months; eyes in the remaining 
      patients showed no worsening of the condition. The mean IOP before switching was 
      15.3 +/- 3.3 mmHg (95% confidence interval 13.9-16.7 mmHg). Following the switch, 
      the mean IOP values were 15.6 +/- 3.3 mmHg (14.1-17.0 mmHg) at 1 month and 
      15.5 +/- 3.3 mmHg (14.1-16.9 mmHg) at 3 months (P = 1.0 at 1 month, P = 1.0 at 
      3 months; both adjusted by Bonferroni correction). No adverse effects were 
      observed. CONCLUSION: Omidenepag isopropyl improved DUES while maintaining IOP in 
      over 70% of Japanese patients with glaucoma who exhibited DUES caused by FP 
      receptor agonists; the improvement was observed within 3 months after switching 
      from FP receptor agonists.
CI  - (c) 2021. Japanese Ophthalmological Society.
FAU - Sakata, Rei
AU  - Sakata R
AD  - Department of Ophthalmology, Graduate of Medicine and Faculty of Medicine, The 
      University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. 
      reisakata-tky@umin.ac.jp.
AD  - Yotsuya Shirato Eye Clinic, Tokyo, Japan. reisakata-tky@umin.ac.jp.
FAU - Fujishiro, Takashi
AU  - Fujishiro T
AD  - Department of Ophthalmology, Graduate of Medicine and Faculty of Medicine, The 
      University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
AD  - Yotsuya Shirato Eye Clinic, Tokyo, Japan.
FAU - Saito, Hitomi
AU  - Saito H
AD  - Department of Ophthalmology, Graduate of Medicine and Faculty of Medicine, The 
      University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
AD  - Yotsuya Shirato Eye Clinic, Tokyo, Japan.
FAU - Nakamura, Natsuko
AU  - Nakamura N
AD  - Department of Ophthalmology, Graduate of Medicine and Faculty of Medicine, The 
      University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
FAU - Honjo, Megumi
AU  - Honjo M
AD  - Department of Ophthalmology, Graduate of Medicine and Faculty of Medicine, The 
      University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
AD  - Yotsuya Shirato Eye Clinic, Tokyo, Japan.
FAU - Shirato, Shiroaki
AU  - Shirato S
AD  - Yotsuya Shirato Eye Clinic, Tokyo, Japan.
FAU - Miyamoto, Etsuyo
AU  - Miyamoto E
AD  - Santen Pharmaceutical Co., Ltd., Osaka, Japan.
FAU - Yamada, Yoshiaki
AU  - Yamada Y
AD  - Santen Pharmaceutical Co., Ltd., Osaka, Japan.
FAU - Aihara, Makoto
AU  - Aihara M
AD  - Department of Ophthalmology, Graduate of Medicine and Faculty of Medicine, The 
      University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
AD  - Yotsuya Shirato Eye Clinic, Tokyo, Japan.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20210720
PL  - Japan
TA  - Jpn J Ophthalmol
JT  - Japanese journal of ophthalmology
JID - 0044652
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Ophthalmic Solutions)
RN  - 0 (Prostaglandins)
RN  - 0 (Receptors, Prostaglandin)
RN  - 0 (prostaglandin F2alpha receptor)
SB  - IM
MH  - Antihypertensive Agents/therapeutic use
MH  - Eyelids
MH  - Female
MH  - *Glaucoma, Open-Angle/diagnosis/drug therapy
MH  - Humans
MH  - Intraocular Pressure
MH  - Male
MH  - Middle Aged
MH  - Ophthalmic Solutions
MH  - Prostaglandins
MH  - *Quality of Life
MH  - Receptors, Prostaglandin
OTO - NOTNLM
OT  - EP2 receptor agonist
OT  - Glaucoma
OT  - Omidenepag isoproryl
OT  - Prostaglandin FP receptor agonists
OT  - Upper eyelid sulcus
EDAT- 2021/07/21 06:00
MHDA- 2021/08/26 06:00
CRDT- 2021/07/20 12:28
PHST- 2020/12/24 00:00 [received]
PHST- 2021/05/28 00:00 [accepted]
PHST- 2021/07/21 06:00 [pubmed]
PHST- 2021/08/26 06:00 [medline]
PHST- 2021/07/20 12:28 [entrez]
AID - 10.1007/s10384-021-00855-3 [pii]
AID - 10.1007/s10384-021-00855-3 [doi]
PST - ppublish
SO  - Jpn J Ophthalmol. 2021 Sep;65(5):591-597. doi: 10.1007/s10384-021-00855-3. Epub 
      2021 Jul 20.